<DOC>
	<DOCNO>NCT02787967</DOCNO>
	<brief_summary>The study conduct asthmatic child age 5 11 year base single-dose , open-label , randomize , 2-way cross-over design Dry Powder Inhaler ( DPI ) fix combination beclometasone dipropionate ( BDP ) 35 μg plus formoterol fumarate ( FF ) 4 μg compare free combination license BDP DPI FF DPI</brief_summary>
	<brief_title>Clinical Pharmacology 35/4 NEXThaler® Children 5-11 Years Old</brief_title>
	<detailed_description>This pharmacokinetic comparison NEXThaler 35/4 μg versus free combination Beclomethasone DPI Formoterol DPI child ( 5 11 year old ) formulation already approve adult .</detailed_description>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male/female child asthma stable enough , accord paediatrician opinion , allow wash period steroid 3 day study treatment . Male/female child asthma regular treatment ICS use shortacting inhaled 2agonist reliever control asthma symptom . Age ≥ 5 &lt; 12 year ( 8 10 child age range 58 year old ) . Children force expiratory volume one second ( FEV1 ) &gt; 70 % predict value ( % pred ) withhold 2agonists treatment minimum 4 h prior screen study treatment . A cooperative attitude ability train proper use DPI , ability use correctly medical device compliant study procedure Past present diagnosis cardiovascular , renal liver disease . Known hypersensitivity active treatmen Exacerbation asthma symptom within 4 week prior screen . Inability perform require breathing technique blood sample . Hospitalization due exacerbation asthma within 1 month prior screen ( Visit 1 ) . Lower respiratory tract infection within 1 month prior screen ( Visit 1 ) . Disease ( asthma ) might influence outcome study . Obesity , i.e . &gt; 97 % weight percentile local standard</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>